Unibest

Pharmaceutical intermediates

Elacestrant Intermediates

8 pharmaceutical intermediates for Elacestrant. Indication: Breast Neoplasms, Metastatic breast cancer.

提交项目All intermediates

About Elacestrant

Originator
Eisai
Indication
Breast Neoplasms, Metastatic breast cancer
Approved Date
01/27/2023
NCE Patent
12/25/2025
DS/DP
01/27/2028

Available intermediates

8 intermediates currently listed for Elacestrant. Request specifications, documentation or a quotation for any item below.

Elacestrant intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
6-(benzyloxy)-3,4-dihydronaphthalen-1(2H)-one32263-70-0//
7-(benzyloxy)-3-bromo-1,2-dihydronaphthalene722536-73-4//
2-(6-(benzyloxy)-3,4-dihydronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane2477812-43-2//
6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol722520-36-7//
(R)-6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol2477812-39-6//
N-ethyl-2-(4-formylphenyl)acetamide2477812-42-1//
2-Bromo-5-Methoxyaniline59557-92-5//
2-Bromo-5-methoxyanilinehydrochloride129968-11-2//

Other programs under E

Edoxaban tosylate monohydrateElagolix SodiumEldecalcitolElinzanetantElobixibatEltrombopagEltrombopag OlamineEluxadoline

Building toward Elacestrant?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →